Clinical significance of lncRNA XIST expression in cholangiocarcinoma and its effect on cell migration and invasion - 28/06/24
Hightlights |
• | XIST may serve as a prognostic biomarker for cholangiocarcinoma. |
• | Overexpression of XIST inhibited tumor progression by targeting miR-126–3p. |
• | XIST has a carcinogenic role in cholangiocarcinoma. |
Abstract |
Background |
Cholangiocarcinoma is a malignant tumor that occurs in the bile duct system, and the prognosis of patients is poor. Currently, research suggests that long non-coding RNAs (lncRNAs) in the treatment and prevention of cholangiocarcinoma. This study primarily focuses on the regulation and potential mechanism of the lncRNA XIST (XIST) in cholangiocarcinoma.
Methods |
The levels of XIST and miR-126–3p in cholangiocarcinoma tissues and cells were detected using real-time quantitative polymerase chain reaction (RT-qPCR). Cell transfection status, including migration and invasion, was examined via the Transwell method. The relationship between XIST and miR-126–3p was observed by dual-luciferase gene reporter assay and verified by rescue assays. Additionally, the prognostic significance of XIST in cholangiocarcinoma was determined using Kaplan-Meier and multivariate Cox regression analyses.
Results |
XIST expression was increased in cholangiocarcinoma, while miR-126–3p was decreased, in both tissues and cells. The successful construction of silencing XIST was found to inhibit the count of cell migration and invasion. XIST directly targeted miR-126–3p to regulate the progression of cholangiocarcinoma.
Conclusion |
XIST sponging miR-126–3p inhibited the progression of cholangiocarcinoma and improved the prognosis for patients. This finding provides new insights and opportunities for future studies on cholangiocarcinoma prognostic biomarkers.
Il testo completo di questo articolo è disponibile in PDF.Keywords : lncRNA XIST, miR-126–3p, Cholangiocarcinoma, Prognostic biomarker
Mappa
Vol 48 - N° 7
Articolo 102398- Agosto 2024 Ritorno al numeroBenvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.
Già abbonato a @@106933@@ rivista ?